How to Read This Checklist
A venture term sheet is a short document with long consequences. The substantive terms are non-binding, but they become the blueprint for the definitive documents — and, more importantly, the precedent for every future round. As Y Combinator's general counsel put it in YC's published walkthrough of a standard and clean Series A term sheet: when an investor says they are betting everything on you but insists on terms that say otherwise, believe the terms. A contract allocates risk, and non-standard clauses tell you precisely which risks the investor is trying to structure away — and how they may behave when things get hard.
The good news is that "standard" is not a matter of opinion. The NVCA model legal documents — the template set most U.S. venture law firms draft from — mark negotiable provisions in brackets, so you can see exactly where a term sheet deviates from the accepted baseline. YC publishes its own single-page standard term sheet, and Cooley GO offers free financing document generators built on the same market conventions. This guide covers the six deviations that do the most damage, in rough order of economic impact. For the full clause-by-clause map of a term sheet, start with our complete term sheet guide.
Red Flag #1: Participating Preferred (the Double Dip)
What it says: the investor's preferred stock is "participating" — on an exit, the investor receives its liquidation preference first and then also shares pro rata in the remaining proceeds alongside common stockholders.
Why it hurts: the market-standard structure, 1x non-participating preferred, forces a choice — take the preference or convert to common, whichever is worth more. Participation removes the choice and pays the investor twice. YC's standard term sheet commentary lists participating preferred by name among the "dirty" economic terms its clean example deliberately excludes.
Worked example (hypothetical numbers): an investor puts in $10M for 20% of your company and you later sell for $50M. With 1x non-participating preferred, the investor takes the better of $10M (the preference) or $10M (20% of $50M) — either way, $10M, leaving $40M for common. With participating preferred, the investor takes the $10M preference first, then 20% of the remaining $40M — another $8M — for $18M total. Common holders get $32M instead of $40M. The extra $8M came out of the founders' and employees' side of the table, at a perfectly respectable exit price. Run your own numbers in our cap table simulator.
The counter: hold the line at 1x non-participating. If the investor will not move, negotiate a participation cap (a total-return ceiling, after which the investor must convert) — a capped structure is meaningfully better than uncapped, though still worse than the standard. Our liquidation preference guide traces capped and uncapped payouts across a full range of exit values.
Red Flag #2: Liquidation Preference Above 1x
What it says: the preference is expressed as "2x" or "3x" — the investor receives a multiple of its invested capital before any proceeds reach common stock.
Why it hurts: a multiple raises the exit value your company must clear before founders and employees see a dollar, and it pushes the conversion crossover — the point where the investor does better converting to common — far out into outlier-exit territory. YC's standard term sheet commentary flags a liquidation preference greater than 1x as the first item on its list of non-standard economic terms.
Worked example (hypothetical numbers): same deal — $10M for 20%. At a $60M exit with a 1x non-participating preference, the investor converts (20% of $60M = $12M beats the $10M preference) and common receives $48M. Swap in a 3x preference and the investor instead takes $30M off the top — half the company's sale price — leaving $30M for everyone else. The crossover moves from $50M to $150M: at every exit below $150M, the multiple, not ownership, dictates the split. And multiples stack — if your Series A carries 2x and your Series B lead demands the same precedent, the preference wall in front of common stock grows with every round.
The counter: treat any multiple above 1x as a significant, priced concession — appropriate (if ever) in bridge or distressed financings, not in a competitive priced round. If you must concede it, extract something explicit in return: a higher valuation, non-participation, or a sunset that steps the multiple back to 1x after a defined period or milestone.
Red Flag #3: Full-Ratchet Anti-Dilution
What it says: if the company ever issues stock below the investor's price, the investor's conversion price resets all the way down to the new price — regardless of how few shares the new issuance involves.
Why it hurts: the standard mechanism, broad-based weighted average, adjusts the conversion price proportionally — a small down round produces a small adjustment. Full ratchet ignores proportionality entirely. The NVCA model documents present the anti-dilution provision with bracketed alternatives precisely because this choice is negotiated, and the broad-based weighted average formula is the option virtually all founder counsel will tell you to insist on.
Worked example (hypothetical numbers): your Series A investor paid $10 per share for 1M shares ($10M). Two years later, you raise a small $1M bridge at $5 per share to reach profitability. Under full ratchet, that $1M financing reprices the entire $10M Series A to $5 — the investor's preferred now converts into 2M shares instead of 1M, and the doubling comes out of common. Under broad-based weighted average, the same bridge produces only a modest adjustment, because the formula weighs the new money against the whole capitalization. The punishment under full ratchet is wildly disproportionate to the dilutive event.
The counter: insist on broad-based weighted average with standard carve-outs (option grants, advisor shares, strategic issuances), and consider pay-to-play language so investors must fund their pro rata in a down round to keep the protection. The formula, the carve-outs, and the negotiation playbook are covered in our anti-dilution guide.
Red Flag #4: A Broad or Open-Ended No-Shop
What it says: from signing, the company may not solicit, encourage, or accept competing offers for a stated exclusivity period — and in the red-flag version, that period is long (well past a realistic closing timeline), renews or has no fixed end, or covers not just financing offers but acquisition interest and "any discussions" with other investors.
Why it hurts: the no-shop is one of the only provisions in a term sheet that is binding. Everything else can still fall apart in diligence — but while the no-shop runs, your alternatives expire and your leverage decays week by week. An investor who insists on unusually long exclusivity is buying a free option on your company: they can slow-walk diligence, watch another month of your numbers, and retrade the price knowing you cannot take a competing call.
The counter: scope and clock. Match the exclusivity period to the realistic closing timeline for your round rather than accepting a long default, and add an automatic termination if the investor misses its own milestones — for example, the no-shop expires early if definitive drafts have not been delivered by a set date. Confine the covered conduct to soliciting competing financing offers. A reasonable investor closing in good faith loses nothing from any of these edits, which is exactly why resistance to them is informative.
Red Flag #5: Tranche-Based Funding
What it says: instead of wiring the full round at closing, the investor funds in stages — say, half now and half upon "achievement of milestones to be mutually agreed" or specific revenue, product, or hiring targets.
Why it hurts: a tranche converts one financing into a sequence of renegotiations. Milestones written at term-sheet speed are almost never as objective as they look — "launch v2" and "reach $2M ARR" leave enormous room for interpretation, and the investor typically holds sole or practical discretion over whether a milestone was "achieved." If the market turns or the investor's enthusiasm cools, the unfunded tranche becomes leverage to reprice the round midstream. Meanwhile you have announced a round you may only receive half of, planned a hiring budget against capital that is not committed in any practical sense, and pinned your runway to someone else's judgment call. Milestone-based incentives also distort operating decisions: you will manage to the tranche trigger, not to the business.
The counter: push for the full amount at closing — that is the norm in standard priced rounds. If a tranche is genuinely non-negotiable (more common in biotech and deep tech, where capital plans map to technical milestones), make the triggers objective, measurable, and pre-agreed in the definitive documents; require that satisfaction be determined by defined criteria rather than investor discretion; and size the first tranche so the company can reach the milestone without assuming the second ever arrives.
Red Flag #6: Board Control Traps
What it says: the voting agreement establishes a board where founders do not hold a majority — most commonly a 2-2-1 structure (two founders, two investors, one independent) at the first priced round — or gives the investor the practical right to designate the "independent" seat. A softer variant adds a side provision requiring the investor director's approval for operational decisions: budgets, executive hires and fires, new lines of business.
Why it hurts: board control is lost through structure, not through any single vote. YC's term sheet commentary is blunt on this point: the 2-2-1 board is the way founders most often lose control at Series A, and the loss matters most because it means the founders can be fired from their own company. The founder-friendly baseline in YC's standard document keeps founders in control 2-1, with the investor holding one seat. Watch the mechanics, not just the seat count: who designates the independent director, whether a founder's right to vote for board seats is conditioned on remaining employed, and whether "standard" protective provisions have quietly expanded to cover routine operating decisions like signing customer contracts or setting the annual budget.
The counter: at seed and Series A, hold a common-majority board (2-1 with the lead investor, or 3-2 at five seats) and require the independent seat to be mutually agreed. Keep protective provisions to the NVCA-standard list — vetoes over new senior securities, charter changes, a sale of the company — and out of day-to-day operations. Definitions matter as much as structure here; our VC glossary covers the terms of art (protective provisions, drag-along, voting agreement) that these clauses are built from.
The Six Red Flags at a Glance
Use this table as a first-pass screen when a term sheet lands. "Market standard" reflects the baseline presented by the NVCA model documents and YC's standard Series A term sheet.
| Clause | Market standard | Red-flag version | Your counter |
|---|---|---|---|
| Liquidation preference | 1x non-participating | Participating ("double dip"), especially uncapped | Hold at non-participating; if forced, add a total-return cap |
| Preference multiple | 1x | 2x-3x of invested capital before common is paid | Trade for higher valuation or a sunset back to 1x |
| Anti-dilution | Broad-based weighted average, with carve-outs | Full ratchet — any down round fully reprices the round | Broad-based weighted average + pay-to-play |
| No-shop | Short exclusivity matched to the closing timeline; financing offers only | Long or renewing exclusivity, broad scope, no expiry conditions | Cap the period; auto-expire if drafts slip; limit scope to financing |
| Funding structure | Full amount wired at closing | Tranches gated on vague or investor-judged milestones | Full funding; if tranched, objective pre-agreed triggers |
| Board | Common-majority board (e.g., 2-1); independent mutually agreed | 2-2-1 at Series A; investor-picked "independent"; operational vetoes | Keep common majority; mutual consent on independent; NVCA-scope vetoes only |
A Note for Emerging GPs Reading From the Other Side
If you are a new fund manager or syndicate lead reviewing — or drafting — these documents, the red flags cut the other way. Asking for participating preferred, a preference multiple, or a tranche as a first-time lead does not read as sophistication; it reads as fear, and it telegraphs exactly the message YC's commentary describes: an investor trying to structure away venture risk instead of underwriting it. It also creates practical problems for your own deal. Downstream leads frequently require non-standard terms from earlier rounds to be cleaned up as a condition of investing, which puts you in the awkward position of defending — or surrendering — the structure you fought for. And founders talk: your term sheet is a marketing document that circulates through accelerator groups and founder communities long after the deal closes.
The stronger play for an emerging GP is the one the public baselines already encode: lead with NVCA-standard or YC-standard paper, negotiate the terms that genuinely price risk (valuation, round size, pro rata), and let clean documents be part of your pitch. When you co-invest behind a larger lead, read their term sheet against this same checklist — the red flags above bind your LPs' money to whatever structure the lead negotiated.
What to Do When You Spot One
A red flag is a prompt for a conversation, not an automatic walk-away. Work the process: first, benchmark the clause against the NVCA model documents and YC's standard term sheet so you can name the deviation precisely — "this is participating preferred; the standard is non-participating" lands very differently than "this feels aggressive." Second, ask the investor why the deviation is there. Legitimate answers exist (bridge dynamics, unusual risk, sector-specific milestone financing); evasive answers are themselves data. Third, engage counsel that does venture financings regularly — a term sheet review is cheap relative to what these clauses cost at exit, and firms' own public resources (Cooley GO among them) show you what their standard paper looks like before you ever pay for an hour. Finally, negotiate in trades, not vetoes: prioritize the two or three clauses that actually move your outcome and give ground on the ones that do not.
And remember the precedent effect. Every clause you accept in this round becomes the floor for the next one — later investors will ask for at least what earlier investors received, and existing investors rarely surrender rights they already hold. That is the real cost of a red-flag term: not just this round's economics, but every round after it. If you are gearing up for your first institutional round, our Series A guide covers the fundraise process end to end.